Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04673877 · ClinicalTrials.gov registry record · Phase 1
Vancomycin Tissue Concentrations by Bier Block or Intravenous Administration
A Phase 1 study of Infection and Hand Injuries, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04673877 is a Phase 1 study of Infection and Hand Injuries that has completed, run by Mayo Clinic. The registered enrollment target is 20 participants, below the 726-participant average among 41 other Infection trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04673877, a Phase 1 study of Infection and Hand Injuries, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether or not giving a lower dose of antibiotics (Vancomycin) in the area where it is needed (upper extremity) is more effective at preventing infection than the current standard dose which is given intravenously (IV).
Conditions Studied
Interventions
- DRUG Vancomycin
- DRUG Systemic IV Vancomycin
- PROCEDURE Bier Block
Study Locations (1)
Arizona
- Mayo Clinic in Arizona - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-08-26 |
| Est. Completion | 2022-08-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04673877
The ClinicalTrials.gov registry entry for NCT04673877 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 726-participant average among 41 other Infection trials with a reported enrollment target (97% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Infection appearing as the primary indexed condition, and to 3 interventions - of which Vancomycin is the first listed.
NCT04673877 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT04673877 about?
NCT04673877 is a clinical study titled "Vancomycin Tissue Concentrations by Bier Block or Intravenous Administration". The purpose of this study is to determine whether or not giving a lower dose of antibiotics (Vancomycin) in the area where it is needed (upper extremity) is more effective at preventing infection than the current standard dose which is given intravenously (IV).
What is the current status of trial NCT04673877?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2021-08-26. Estimated completion is 2022-08-17.
What conditions does trial NCT04673877 study?
This clinical trial studies the following conditions: Infection, Hand Injuries, Hand Arthritis, Hand Injury Wrist, Hand Injuries and Disorders.
What interventions are being tested in trial NCT04673877?
The interventions under investigation include: Vancomycin (DRUG), Systemic IV Vancomycin (DRUG), Bier Block (PROCEDURE).
Who is sponsoring clinical trial NCT04673877?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04673877 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
RECRUITING · Phase 1
-
Pharmacokinetics and Safety of Cefazolin 2g in DUPLEX
COMPLETED · Phase 1
-
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation
COMPLETED · Phase 1
-
Triple Dye Plus Alcohol Versus Triple Dye Alone for Newborn Umbilical Cord Care
COMPLETED · Phase 1
-
Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma
COMPLETED · Phase 1
-
Home Hospital for Suddenly Ill Adults
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.